Announcements
| Date | Title | |
|---|---|---|
| 29 July 2010 | Notice of filing of First Half 2010 financial report |
 |
| 28 July 2010 | Recordati: positive first half 2010 results, ebit and net income increase |
|
| 15 July 2010 | Recordati: positive conclusion to the Decentralized Procedure for the approval in Europe of pitavastatin (Livazo®) |
|
| 8 June 2010 | Recordati enters the Romanian market |
|
| 7 May 2010 | Recordati signs an agreement with Zambon for the co-marketing of silodosin in France |
|
| 6 May 2010 | Recordati: positive first quarter 2010 results, sales and income increase. Three year business plan updated |
|
| 27 April 2010 | Recordati to meet with the financial community and specialized press in Milan |
|
| 13 April 2010 | Dividend payment for the financial year 2009 |
|
| 13 April 2010 | Recordati: shareholders approve the 2009 accounts. Dividend € 0.275 per share (+10.0%) |
|
| 7 April 2010 | Recordati signs co-marketing agreement with Esteve in Spain for pitavastatin |
|
| 26 March 2010 | Recordati: documents of the annual Shareholders'meeting of 13th April 2010 (1st call) and 16th April 2010 (2nd call) |
|
| 19 March 2010 | Recordati: Carbaglu® approved by the FDA for use in the U.S.A. |
|
| 15 March 2010 | Recordati and Leespharm announce partnership for Zanidip® in China |
|
| 11 March 2010 | Notice of Annual Shareholders' Meeting to be held on 13 April 2010 |
|
| 5 March 2010 | Recordati: 2009 accounts approved by the board. Net income € 110.6 million. Dividend per share € 0.275 (+10%) |
|
| 11 February 2010 | Recordati: preliminary full year 2009 results in line with targets: revenues +8.4%, net income +10.1% |
|
| 3 February 2010 | Recordati: silodosin (Urorec®/Silodyx™) approved by the European Commission for the treatment of the signs and symptoms of BPH |
|
| 20 November 2009 | Recordati: EMEA/CHMP adopts a positive opinion for silodosin (brands Urorec® and Silodyx™) |
|
| 27 October 2009 | Recordati: positive first nine months 2009 results, sales and income increase |
|
| 29 July 2009 | Recordati signs a license agreement with Pharmaplan for silodosin in South Africa |
|
| 29 July 2009 | Recordati signs an agreement with Nycomed for the co-marketing of silodosin in Italy |
|
| 28 July 2009 | Recordati: positive first half 2009 results, sales and income increase |
|
| 14 July 2009 | Recordati announces revenues up 8.9% in the first half 2009 |
|
| 13 July 2009 | Recordati obtains TransAct LAT® license from Amdipharm |
|
| 6 May 2009 | Recordati: positive first quarter 2009 results |
|
| 15 Aprile 2009 | Recordati launches Zanextra® in France |
|
| 7 April 2009 | Recordati: shareholders approve the 2008 accounts. Dividend € 0,25 per share (+16.3%) |
|
| 3 April 2009 | Recordati signs co-marketing agreement with Almirall in Spain for silodosin |
|
| 3 March 2009 | Recordati: 2008 accounts approved by the board. Net income +18.3%. Dividend per share € 0.25 |
|
| 11 February 2009 | Recordati: preliminary full year 2008 results in line with targets: revenues +9.7%, net income +18.3% |
|
| 19 January 2009 | Recordati acquires Herbaco-Bofarma in the Czech Republic |
|
To view PDFs you need the Adobe Acrobat Reader. This program is available free of charge from the Adobe website.
